PROMETHEE: PROtein S100B for Mild Trauma of the HEad in Emergency Patients

Sponsor
Centre Hospitalier Princesse Grace (Other)
Overall Status
Completed
CT.gov ID
NCT03313505
Collaborator
(none)
787
15
38.3
52.5
1.4

Study Details

Study Description

Brief Summary

Brain injury is a frequent purpose for consultation in emergency services. Management of brain injury is time and resource consuming, combining clinical monitoring and imaging.

The stage prior to the management of the victims of brain injury is stratification of the severity, potential or proven.

Severe brain injury requires emergent brain CT-scan, ideally within one hour of the first medical contact. Patients requiring this strategy present with focused neurological deficit, Glasgow score <15 to 2 hours after the trauma, suspicion of open fracture of the skull or dish pan fracture, any signs of fracture of the skull base (hemotympanum, bilateral peri-orbital ecchymosis), otorrhea or rhinorrhea of cerebrospinal fluid, more than one episode of vomiting in adults, and posttraumatic convulsion. Patients benefiting from anticoagulant therapy are included in this category.

Victims of brain injury that do not fall into this category are considered less critical.

By definition, mild traumatic brain injury :
  • a trauma of the cephalic extremity :

  • whose Glasgow score (30 min after the trauma or during the consultation) is 13-15,

  • associated with one or more of the following: confusion; disorientation; loss of consciousness of 30 min or less; post-traumatic amnesia of less than 24 hours; other transient neurological abnormalities (focal signs, epileptic seizures, non-surgical intracranial lesion).

Among these patients, some are considered at risk of developing intracerebral lesions. Nevertheless, it should be noted that the prevalence of hemorrhagic complications is radically different between patients with a Glasgow score of 13 and those with a score of 15. Thus, the recommendations suggest a brain scan without injection of contrast media within 4 to 8 hours for patients with the following characteristics :

  • a retrograde amnesia of more than 30 minutes,

  • a loss of consciousness or amnesia associated with:

  • either a risk mechanism (pedestrian overturned by a motor vehicle, ejection of a vehicle, falling by more than one meter),

  • or an age> 65 years,

  • or coagulation disorders, including the use of platelet aggregation therapy. Patients who fall outside this definition are considered low risk of complication and should not benefit of imaging.

Data from the scientific literature show that an early brain CT-scan allows identification of post-traumatic lesions in this population. Nevertheless, organizational problems, including the availability of the imaging, radiation, and disruption of surveillance related to patient displacement, are limitations to this strategy. In contrast, the low cost-effectiveness of CT scan is often advocated in patients with mild traumatic brain injury. For example, in the Octopus study, 52 of 1316 patients who received CT scan after mild head trauma had an intracerebral lesion. Among these patients, 39 (3%) had intracerebral lesion related to trauma; for 13 (1%) patients, the link with the trauma was uncertain.

In fact, the search of alternatives for a safer, more conservative, more efficient practice, one of the objectives of which is to limit the undue use of cerebral scanning. Thus, many teams have been interested in the use of biological variables to guide the decision to use imagery.

Among candidate biomarkers, the S100B protein has been the subject of many evaluations which allow it to be used in current practice. Indeed, the increase of the S100B protein carried out within 3 hours following a mild head trauma makes it possible to identify the patients at risk of intracerebral lesion and to target the indications of imaging.

The purpose of the registry is to describe the use, interpretation and performance of the S100B protein in its use at bedside in emergency medicine.

Condition or Disease Intervention/Treatment Phase
  • Biological: S100B protein dosage
  • Other: Brain CT scan

Study Design

Study Type:
Observational
Actual Enrollment :
787 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
PROtein S100B for Mild Trauma of the HEad in Emergency Patients
Actual Study Start Date :
May 14, 2018
Actual Primary Completion Date :
Jul 15, 2021
Actual Study Completion Date :
Jul 22, 2021

Arms and Interventions

Arm Intervention/Treatment
Patients who had been tested for S100B protein

Biological: S100B protein dosage
S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient

Patients who have benefited from another strategy

Other: Brain CT scan
No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient

Outcome Measures

Primary Outcome Measures

  1. Evaluation of the number of brain CT-scan saved in patients who have been tested for S100B protein [53 weeks]

    Percentage (%)

Secondary Outcome Measures

  1. Comparison of supported patients with S100B protein assay or without S100B protein assay [53 weeks]

    Percentage (%)

  2. Intensive treatment comparison of the patients included in the centers that carried out an "intensive implementation" of the use of the S100B protein and those included in the centers that provided the S100B protein [53 weeks]

    Percentage (%)

  3. Quantification and evaluation of deviations to the algorithm [53 weeks]

    Percentage (%)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult Patients

  • Victims of mild head trauma at risk of complication :

o Adult patients with head trauma with:

  • retrograde amnesia of more than 30 minutes, or

  • loss of consciousness or amnesia of the facts associated with:

  • Either a risky mechanism (pedestrian overturned by a motor vehicle, ejection of a vehicle, drop of more than one meter),

  • either An age> 65 years,

  • Either clotting disorders, including platelet aggregation therapy.

  • either Glasgow Score to 15

  • Admitted to the emergency department within three hours of the traumatic event.

Exclusion Criteria:
  • Refusal to participate at the study

  • Patients with obstacle to 7 days follow up

  • Pregnant women

  • Patients not subject to an health insurance scheme in France or Monaco.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire de Clermont-Ferrand Clermont-Ferrand France 63003
2 AP-HP Centre Hospitalier Universitaire Henri-Mondor Créteil France 94000
3 Hospices Civils de Lyon - Pôle Est Lyon France 69002
4 AP-HM La Timone Marseille France 13915
5 Centre Hospitalier de Metz-Thionville Metz France 57085
6 Centre Hospitalier Universitaire de Nice, Hôpital Pasteur Nice France 06000
7 Centre Hospitalier Universitaire de Nîmes - Hôpital Carémeau Nîmes France 30029
8 AP-HP Nord Lariboisière Paris France 75010
9 AP-HP Sud Pitié-Salpêtrière Paris France 75013
10 Centre Hospitalier Universitaire de Poitiers Poitiers France 86000
11 Hôpital Charles Nicolle Rouen France 76031
12 CHU de Strasbourg Strasbourg France
13 HIA Sainte Anne Toulon France 83800
14 Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan Toulouse France 31059
15 Centre Hospitalier Princesse Grace Monaco Monaco 98000

Sponsors and Collaborators

  • Centre Hospitalier Princesse Grace

Investigators

  • Study Director: Yann-Erick CLAESSENS, PU-PH, Centre Hospitalier Princesse Grace
  • Study Director: Karim TAZAROURTE, PU-PH, Hospices Civils de Lyon

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Princesse Grace
ClinicalTrials.gov Identifier:
NCT03313505
Other Study ID Numbers:
  • 16-09
  • 2016-A00901-50
First Posted:
Oct 18, 2017
Last Update Posted:
Jul 29, 2021
Last Verified:
Jul 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 29, 2021